Systematic Financial Management LP lessened its holdings in shares of Horizon Therapeutics PLC (NASDAQ:HZNP) by 43.5% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 19,990 shares of the biopharmaceutical company’s stock after selling 15,365 shares during the quarter. Systematic Financial Management LP’s holdings in Horizon Therapeutics were worth $544,000 at the end of the most recent quarter.
A number of other institutional investors and hedge funds have also made changes to their positions in HZNP. Nuveen Asset Management LLC raised its holdings in Horizon Therapeutics by 1,910.0% in the 2nd quarter. Nuveen Asset Management LLC now owns 1,672,839 shares of the biopharmaceutical company’s stock valued at $40,249,000 after buying an additional 1,589,614 shares during the period. Price T Rowe Associates Inc. MD grew its position in shares of Horizon Therapeutics by 1,774.4% during the second quarter. Price T Rowe Associates Inc. MD now owns 1,101,748 shares of the biopharmaceutical company’s stock worth $26,508,000 after buying an additional 1,042,969 shares in the last quarter. Rhenman & Partners Asset Management AB acquired a new position in shares of Horizon Therapeutics during the third quarter worth about $27,911,000. Renaissance Technologies LLC grew its position in shares of Horizon Therapeutics by 11.4% during the second quarter. Renaissance Technologies LLC now owns 8,754,275 shares of the biopharmaceutical company’s stock worth $210,628,000 after buying an additional 896,500 shares in the last quarter. Finally, D. E. Shaw & Co. Inc. grew its position in shares of Horizon Therapeutics by 15.8% during the second quarter. D. E. Shaw & Co. Inc. now owns 5,097,929 shares of the biopharmaceutical company’s stock worth $122,656,000 after buying an additional 695,950 shares in the last quarter. 86.44% of the stock is currently owned by institutional investors.
Shares of HZNP stock traded up $0.45 during trading hours on Friday, hitting $30.26. The stock had a trading volume of 1,246,600 shares, compared to its average volume of 1,287,077. The company has a debt-to-equity ratio of 0.87, a current ratio of 2.33 and a quick ratio of 2.23. The firm has a market capitalization of $5.68 billion, a PE ratio of 16.54, a PEG ratio of 1.82 and a beta of 0.83. Horizon Therapeutics PLC has a twelve month low of $17.94 and a twelve month high of $31.25. The stock’s 50 day moving average is $28.14 and its 200 day moving average is $26.11.
In related news, CEO Timothy P. Walbert sold 56,836 shares of the stock in a transaction on Wednesday, August 21st. The stock was sold at an average price of $28.00, for a total transaction of $1,591,408.00. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, EVP Brian K. Beeler sold 12,475 shares of the stock in a transaction on Tuesday, November 5th. The shares were sold at an average price of $30.02, for a total value of $374,499.50. The disclosure for this sale can be found here. Insiders sold 576,405 shares of company stock worth $16,126,099 in the last three months. 4.10% of the stock is owned by corporate insiders.
A number of equities analysts have recently commented on the company. Cowen set a $35.00 price objective on Horizon Therapeutics and gave the stock a “buy” rating in a research report on Wednesday, August 7th. ValuEngine downgraded Horizon Therapeutics from a “buy” rating to a “hold” rating in a research report on Thursday, September 5th. Guggenheim assumed coverage on Horizon Therapeutics in a research report on Thursday, September 12th. They set a “buy” rating and a $36.00 price objective for the company. Stifel Nicolaus set a $35.00 price objective on Horizon Therapeutics and gave the stock a “buy” rating in a research report on Friday, September 13th. Finally, BidaskClub raised Horizon Therapeutics from a “hold” rating to a “buy” rating in a research report on Thursday, October 31st. Three research analysts have rated the stock with a hold rating and twelve have given a buy rating to the stock. The company currently has a consensus rating of “Buy” and a consensus target price of $33.77.
Horizon Therapeutics Company Profile
Horizon Therapeutics Public Limited Company, a biopharmaceutical company, focuses on researching, developing, and commercializing medicines that address unmet treatment needs for rare and rheumatic diseases in the United States and internationally. Its orphan and rheumatology marketed medicines include KRYSTEXXA, a medicine for the treatment of uncontrolled gout; RAVICTI for use as a nitrogen-binding agent for chronic management of adult and pediatric patients; PROCYSBI for nephropathic cystinosis, a rare and life-threatening metabolic disorder; ACTIMMUNE for chronic granulomatous disease; RAYOS for the treatment of multiple conditions, rheumatoid arthritis; BUPHENYL tablets for oral administration and BUPHENYL powder for oral, nasogastric, or gastrostomy tube administration; and QUINSAIR, a formulation of the antibiotic drug levofloxacin for the management of chronic pulmonary infections due to Pseudomonas aeruginosa in adult patients with cystic fibrosis.
Want to see what other hedge funds are holding HZNP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Horizon Therapeutics PLC (NASDAQ:HZNP).
Receive News & Ratings for Horizon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.